Shares of Cardiome Pharma Corporation (NASDAQ:CRME) (TSE:COM) have earned an average rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $6.42.

A number of equities analysts recently commented on CRME shares. Zacks Investment Research raised Cardiome Pharma from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Wednesday, November 1st. HC Wainwright reissued a “buy” rating and set a $9.50 price target on shares of Cardiome Pharma in a research note on Wednesday, November 22nd. ValuEngine lowered Cardiome Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Canaccord Genuity set a $5.00 price target on Cardiome Pharma and gave the company a “buy” rating in a research note on Wednesday, November 15th. Finally, Mackie raised Cardiome Pharma to a “buy” rating in a research note on Friday.

Cardiome Pharma (CRME) traded up $0.06 during midday trading on Friday, hitting $1.49. The stock had a trading volume of 81,388 shares, compared to its average volume of 110,982. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71. Cardiome Pharma has a 1 year low of $1.29 and a 1 year high of $4.84.

Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last released its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). Cardiome Pharma had a negative return on equity of 94.68% and a negative net margin of 112.91%. The business had revenue of $6.02 million during the quarter, compared to the consensus estimate of $7.42 million. During the same period last year, the company earned ($0.19) EPS. The business’s revenue was up 14.9% on a year-over-year basis. equities research analysts predict that Cardiome Pharma will post -0.84 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in shares of Cardiome Pharma by 37.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 155,095 shares of the biopharmaceutical company’s stock valued at $701,000 after purchasing an additional 42,416 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Cardiome Pharma by 17.9% in the 1st quarter. Renaissance Technologies LLC now owns 253,413 shares of the biopharmaceutical company’s stock valued at $763,000 after purchasing an additional 38,400 shares during the last quarter. AlphaOne Investment Services LLC lifted its stake in shares of Cardiome Pharma by 14.9% in the 2nd quarter. AlphaOne Investment Services LLC now owns 632,739 shares of the biopharmaceutical company’s stock valued at $2,860,000 after purchasing an additional 82,027 shares during the last quarter. Stonepine Capital Management LLC lifted its stake in shares of Cardiome Pharma by 79.7% in the 3rd quarter. Stonepine Capital Management LLC now owns 2,866,785 shares of the biopharmaceutical company’s stock valued at $6,106,000 after purchasing an additional 1,271,236 shares during the last quarter. Finally, Westfield Capital Management Co. LP lifted its stake in shares of Cardiome Pharma by 8.0% in the 2nd quarter. Westfield Capital Management Co. LP now owns 5,286,340 shares of the biopharmaceutical company’s stock valued at $23,894,000 after purchasing an additional 391,392 shares during the last quarter. 52.48% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Cardiome Pharma Corporation (CRME) Receives Average Recommendation of “Buy” from Analysts” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/12/15/cardiome-pharma-corporation-crme-receives-average-recommendation-of-buy-from-analysts.html.

Cardiome Pharma Company Profile

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.